Systemic lupus erythematosus and cardiovascular disease

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Cardiovascular disease (CVD) remains a significant challenge in systemic lupus erythematosus (SLE) despite improved overall prognosis.
• The risk of CVD is substantially elevated in SLE patients compared to the general population.
• Atherosclerosis, a key driver of CVD, is more prevalent in SLE, characterized by inflammatory processes and immune system dysregulation.

Purpose of the Study:

• To elucidate the multifaceted mechanisms contributing to the increased CVD risk in SLE.
• To identify both traditional and non-traditional risk factors implicated in SLE-related cardiovascular complications.
• To emphasize the importance of comprehensive risk factor management in SLE patients.

Main Methods:

• Review and synthesis of existing literature on CVD in SLE.
• Analysis of the roles of atherosclerosis, antiphospholipid antibodies (aPL), and inflammation in SLE pathogenesis.
• Examination of the impact of traditional risk factors (hypertension, dyslipidemia) and non-traditional factors (aPL, anti-PC antibodies) on CVD risk.

Main Results:

• Atherosclerosis, driven by inflammation and immune factors like oxidized LDL and impaired cellular debris clearance, is a primary contributor to CVD in SLE.
• Antiphospholipid antibodies (aPL) promote thrombosis and endothelial dysfunction, significantly increasing arterial and venous risks.
• Low levels of antibodies against phosphorylcholine (anti-PC) are associated with higher CVD and atherosclerosis risk in SLE patients.

Conclusions:

• The elevated CVD risk in SLE is a complex interplay of traditional factors (hypertension, dyslipidemia) and non-traditional factors, notably aPL and inflammation.
• Specific immune markers, such as antiphospholipid antibodies (aPL) and anti-phosphorylcholine (anti-PC) antibodies, play critical roles.
• Close monitoring and management of both traditional and non-traditional risk factors, alongside SLE disease activity, are essential for mitigating CVD in affected individuals.